NCT06097260

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

Terminated Phase 2 Last updated 1 August 2025

What this trial tests

Phase 2 trial testing PLN-74809 in Idiopathic Pulmonary Fibrosis in 320 participants. Terminated before completion.

Timeline

16 November 2023

Primary endpoint
4 April 2025

4 April 2025

Quick facts

Lead sponsor	Pliant Therapeutics, Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	320
Start date	16 November 2023
Primary completion	4 April 2025
Estimated completion	4 April 2025
Sites	268 locations across Italy, Japan, Taiwan, Poland, South Korea, Denmark, New Zealand, Netherlands

Drugs / interventions tested

• PLN-74809 — full drug profile →
• Placebo

Conditions studied

• Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →

Sponsor

Pliant Therapeutics, Inc. — full company profile →

Who can join

40 and older, any sex, with Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial.
   Lancaster L, Cottin V, Ramaswamy M, Wuyts WA, et al · · 2024 · cited 48× · PMID 38843105 · DOI 10.1164/rccm.202403-0636oc
2. Highlights on Future Treatments of IPF: Clues and Pitfalls.
   Libra A, Sciacca E, Muscato G, Sambataro G, et al · · 2024 · cited 13× · PMID 39125962 · DOI 10.3390/ijms25158392
3. Understanding myofibroblast origin in the fibrotic lung.
   Zabihi M, Shahriari Felordi M, Lingampally A, Bellusci S, et al · · 2024 · cited 9× · PMID 39403408 · DOI 10.1016/j.pccm.2024.08.003
4. Dual α<sub>v</sub>β<sub>6</sub> and α<sub>v</sub>β<sub>1</sub> Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinica
   Montesi SB, Cosgrove GP, Turner SM, Zhou IY, et al · · 2025 · cited 8× · PMID 40153543 · DOI 10.1164/rccm.202410-1934oc
5. What Is on the Horizon for Treatments in Idiopathic Pulmonary Fibrosis?
   Moua T, Baqir M, Ryu JH. · · 2024 · cited 4× · PMID 39518443 · DOI 10.3390/jcm13216304
6. Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF).
   Aribindi K, Liu GY, Albertson TE. · · 2024 · cited 4× · PMID 39192604 · DOI 10.1080/17512433.2024.2396121
7. Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons.
   Giulianelli G, Cocconcelli E, Fiorentù G, Bernardinello N, et al · · 2025 · cited 3× · PMID 40323570 · DOI 10.1007/s41030-025-00296-0
8. Tension-induced organelle stress: an emerging target in fibrosis.
   Kai F, Leidal AM, Weaver VM. · · 2025 · cited 3× · PMID 39818520 · DOI 10.1016/j.tips.2024.12.006